5244042026-01-012026-03-315244042026-03-315244042025-03-315244042025-04-012026-03-315244042026-01-012026-03-31in-capmkt:OtherExpenses1Member5244042025-04-012026-03-31in-capmkt:OtherExpenses1Member5244042026-03-31OtherNoncurrentFinancialAssetsDomain15244042026-03-31OtherNoncurrentAssetsDomain15244042026-03-31OtherNoncurrentAssetsDomain25244042026-03-31OtherNoncurrentAssetsDomain35244042026-03-31OtherCurrentFinancialAssetsDomain15244042026-03-31OtherCurrentFinancialAssetsDomain25244042026-03-31OtherCurrentFinancialAssetsDomain35244042026-03-31OtherNoncurrentFinancialLiabilitiesDomain15244042026-03-31OtherCurrentFinancialLiabilitiesDomain15244042026-03-31OtherCurrentFinancialLiabilitiesDomain25244042026-03-31OtherCurrentLiabilitiesDomain15244042026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15244042025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15244042026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15244042025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15244042026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524404MARKSANSNOTLISTEDINE750C01026MARKSANS PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312026-05-262026-05-12INRMillionsQuarterlyFourth quarterSingle segmentPharmaceutical Formulation2026-05-2611:55:002026-05-2612:45:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated8561140000351740000891288000026497200001498110000-24130000010675600006310000024287000016328400006912900000199998000001999980000575660000-66000000509660000014903200000000149032000053940000020297200001481290000903000019999300002979000045316000013.273.27003.273.27The audited consolidated annual financial results for the year ended 31 March 2026 has been prepared on the basis of the consolidated annual financial statements in accordance with the Indian Accounting Standards (Ind AS) as notified under the Companies (Indian Accounting Standards) Rules 2015 (as amended) specified under section 133 of the Companies Act, 2013 and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation'), as amended were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meeting held on 26 May 2026. The Statutory Auditors of the Company have expressed an unmodified opinion on the audited consolidated financial results for the year ended 31 March 2026 <BR> <BR> The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures in respect of full financial year and the unaudited published year-to-date figures upto 31 December for respective years which were subject to limited review <BR> <BR> The Group's activities comprise of manufacturing pharmaceutical formulation and trading in pharmaceutical products. The Group has only one reportable segment namely 'Pharmaceuticals' as per Ind AS 108 on 'Operating Segments <BR> <BR> Other income (net) includes the following net foreign exchange gain/(loss), including forward contracts: <BR> Description Quarter ended Nine Months ended <BR> 31-Mar-26 31-Dec-25 31-Mar-25 31-Mar-26 31-Mar-25 <BR> <BR> Net gain / (loss) 247.99 118.12 25.51 500.95 193.11 <BR> <BR> During the year, the Board of Directors and Shareholders of the Company had approved the Marksans Employees Stock Option Scheme 2024 ("Scheme") for the employees of the Company and its subsidiary companies comprising of equity shares of the Company, not exceeding 2,300,000 equity share of face value of Rs 1 each. Under the said Scheme, the Company has granted 400,000 equity stock options of face value of Rs 1 each on 24 September 2025 to the eligible employees of the Company and its subsidiary companies <BR> <BR> During the quarter and year ended 31 March 2026, Company has formed and incorporated two new wholly owned subsidiaries, viz. Marksans Pharma (Europe) Limited in Ireland and Marksans (Canada) Inc. in Canada on 16 January 2026 and 22 January 2026 respectively <BR> <BR> The Board of Directors in the meeting held on 26 May 2026 have recommended final dividend of 0.90 per equity share of 1 each 90 percent for the Financial Year 2025-26 <BR> <BR> The above standalone audited annual financials results are available on the Company's website (www.marksanspharma.com) and stock exchanges websites, BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed2025-04-012026-03-31AuditedConsolidated295093800008253300003033471000095920800004544880000-136417000042093400002412500009863200006519460000247291600005605550000056055500001529980000-1250700001404910000042006400000000420064000017614800005962120000417900000021640000589159000070530000453160000109.229.22009.229.22Other Expenses1632840000Other Expenses651946000062500600001478200000452560000729740000438020000000003872000038720000129650000319505000011381620000972281000006445660000634137000035551400000116242000017504590000272274000000038609020000453160000297784000003023156000029524000030526800000000027013000002701300000591500005087000028113200002959100002012000033489700003369090000737880000440288000044901000031800004158300000527090000000808222000038609020000Other financial assets38720000Other non-current assets175540000Non current tax assets (net)10810000Right of use assets3008700000Other current financial assets49260000Other current assets1004620000current tax assets (net)108540000Lease liabilities2701300000Lease liabilities436580000Other current financial liabilities301300000Other current liabilities449010000241250000-387250000-3139000000-81500001070000-1700000-6200000935000000-1894000009863200000800000-20000106400000-22373000002767800000292500000-1163000002521300000372240000597779000000013965400000458125000000000000977000013052700000000000000000000002624700000-1449640000-2482670000000000000-650600003839600003625300002785000000-7092800001389300000-5790000138351000049578600006341370000Remeasurements of the net defined benefit plans34400003440000Remeasurements of the net defined benefit plans13910000139100008700003500000Foreign currency translation reserve (net)536830000536830000Foreign currency translation reserve (net)17510700001751070000005394000001761480000AuditedtrueMSKA & Associates LLPtrue2027-07-31